Novavax starts enrolling people for phase two of COVID-19 vaccine trial

This post was originally published on this site

https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEG7N134_L.jpg

In the new phase, the age range has been expanded, with adults between 60 and 84 years accounting for nearly 50% of the trial’s population.

Early-stage data from a small clinical trial of the vaccine has shown it produced high levels of virus-fighting antibodies, and the company aims to begin larger studies to obtain regulatory approvals as early as December.